Search results for "Janssen"

Target the Core: Why 'Deep Remission' Is the New Gold Standard in Inflammatory Bowel Disease Treatment

Target the Core: Why 'Deep Remission' Is the New Gold Standard in Inflammatory Bowel Disease Treatment

Treatment for inflammatory bowel disease is rapidly moving beyond simple symptom management toward the structural restoration of the intestinal...
Expanded Health Insurance Coverage Lowers Barrier to Care for Rare Heart and Kidney Disorder

Expanded Health Insurance Coverage Lowers Barrier to Care for Rare Heart and Kidney Disorder

Patients suffering from light-chain amyloidosis, a rare and debilitating blood disorder that causes abnormal proteins to accumulate in vital organs,...
South Korean Biotechs Race to Conquer the Untapped Global MASH Market

South Korean Biotechs Race to Conquer the Untapped Global MASH Market

Fat accumulation in the liver can trigger severe inflammation even in individuals who completely abstain from alcohol.
Hanmi Pharm Revives 'LAPSCOVERY' Momentum with $1.26B Eli Lilly Licensing Deal

Hanmi Pharm Revives 'LAPSCOVERY' Momentum with $1.26B Eli Lilly Licensing Deal

Hanmi Pharmaceutical has licensed its novel drug candidate sonefpeglutide to global pharmaceutical giant Eli Lilly and...
Ebola spreads rapidly in DRC—how far have new vaccines and treatments come?

Ebola spreads rapidly in DRC—how far have new vaccines and treatments come?

A Reuters report said the U.K. media outlet The Guardian reported on the 19th (20th in Korea time) that the World...
Oscotec Ramps Up R&D: What Lies Beyond the Success of Lazertinib?

Oscotec Ramps Up R&D: What Lies Beyond the Success of Lazertinib?

“It doesn’t end with lazertinib. Keep an eye out for the next candidate in line.”Oscotec is aggressively channeling the...
When Recurrent Diarrhea Is More Than a Passing Bug: The Rising Threat of IBD in Young Adults

When Recurrent Diarrhea Is More Than a Passing Bug: The Rising Threat of IBD in Young Adults

When recurring abdominal pain and diarrhea strike, most people first assume they are dealing with a standard bout of...
Celltrion Secures Canadian Approval for ‘Steqeyma’ Autoinjector Formulation

Celltrion Secures Canadian Approval for ‘Steqeyma’ Autoinjector Formulation

Celltrion announced on March 20, 2026, that it has received additional approval from Health Canada for the autoinjector...
Huwons Lab SC Formulation Change Platform, Will It Succeed in the Market?

Huwons Lab SC Formulation Change Platform, Will It Succeed in the Market?

Huwons Global's subsidiary Huwons Lab is challenging the formulation change platform business that converts intravenous...